Publications

Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study

Publié en January 2019 JOURNAL OF INVESTIGATIVE DERMATOLOGY
January 2019

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Previous publication
January 2019

Phenotype-endotype in very severe preschool wheezers: The P’titAsthme cohort

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Next publication

Authors